ITMIG2022 Program

NOTE: All times are given in EST!

Check the correct time in your time zone!

September 29

Pathology Workshop

 

08:00 – 09:15 EST – Part 1: Thymic Epithelial Tumors in WHO 2021 histological classification (1 h 15 min)
  1. Thymomas – basic types (15 min)
  2. Thymomas – rare types (15 min)
  3. Thymic carcinomas (TCs) (15 min)
  4. Thymic neuroendocrine tumors (TNETs) (15 min)
  5. Q&A

09:15 – 09:30 EST – BREAK

09:30 – 10:30 EST – Virtual Microscopy Session: Histopathology and Cytopathology of TETs (60 min)
Thymomas – basic and rare types, TCs, TNETs
Q&A

10:30 – 11:00 EST – BREAK

11:00 – 11:45 EST – Part 2: Benign Thymic Disorders (45 min)
  1. Mediastinal cysts (10 min)
  2. Thymic hyperplasias (10 min)
  3. Thymolipomas/Lipofibroadenomas (10 min)
  4. Q&A

11:45 – 12:15 EST – Virtual Microscopy Session: Benign Thymic Disorders (30 min)
Mediastinal cysts, thymic hyperplasias, thymolipomas/lipofibroadenomas
Q&A

12:15 – 12:30 EST – BREAK

12:30 – 13:30 EST – Part 3: Histopathological Report (60 min)
  1. TNM staging (2017) (10 min)
  2. Histopathological report: for resected tumors and for biopsy samples – Pathologist’s perspective (10 min)
  3. What would I like to find in histopathological report? Surgeon’s perspective (10 min)
  4. What would I like to find in histopathological report? Oncologist’s perspective (10 min)
  5. Q&A

September 30

08:00 – 08:15 EST – Opening ceremony (15 min)

08:15 – 09:45 EST –  Session 1: What I always wanted to know from other specialists? (90 min)
  1.  Surgeon’s perspective (7 min)
  2. Radiologist’s perspective (7 min)
  3. Pathologist’s perspective (7 min)
  4. Neurologist’s perspective (7 min)
  5. Radiation oncologist’s perspective (7 min)
  6. Medical oncologist’s perspective (7 min)
  7. Case presentation – Consequences of the lack of communication (10 min)
  8. Q&A (30 min)

09:45 – 10:00 EST – BREAK

10:00 – 11:15 EST – Session 2:  Lymph node involvement in thymic epithelial tumors (1 hr 15 min)
  1. Imaging of mediastinal lymph nodes (CT, MRI, PET/CT) (10 min)
  2. Nodal dissection in TETs – how much is enough? (10 min)
  3. pN factor in pathological report (10 min)
  4. Radiation oncology treatment fields: nodal coverage and target volume delineation (10 min)
  5. Survival in relation to nodal involvement in TET (10 min)
  6. Q&A (25 min)

11:15 – 11:30 EST – BREAK

11:30 – 12:30 EST – POSTER SESSSION

October 1

08:00 – 09:30 EST – Session 3: Lung carcinomas vs. thymic carcinomas (90 min)
  1. The role of minimally invasive surgery in lung carcinomas and in thymic carcinomas (15 min)
  2. Biomarkers for targeted therapies in lung carcinomas and in thymic carcinomas – state-of-the-art and future perspectives (15 min)
  3. Radiation therapy for lung carcinomas and for thymic carcinomas (15 min)
  4. Molecular targeted therapies and immunotherapy in lung carcinomas and in thymic carcinomas (15 min)
  5. Q&A (30 min)

09:30 – 09:45 EST – BREAK

09:45 – 10:55 EST – Session 4: Complications and side effects of the treatment in TETs  (1 hr 10 min)
  1. The most important complications of surgical treatment of TETs (10 min)
  2. Side effects of radiotherapy for TETs (10 min)
  3. Cardiotoxicity and other longterm toxicities of chemotherapy for TETs (10 min)
  4. Autoimmune side effects of immunotherapy for TETs (10 min)
  5. Q&A (30 min)

10:55 – 11:10 EST – BREAK

11:10 -12:30 EST – ORAL ABSTRACT SESSION

October 2

08:00 – 09:10 EST – Session 5: Multi-system syndromes associated with thymic malignancies (70 min)
  1. Multisystem disease features associated with thymic malignancies – setting the clinical scenario and its relevance (10 min)
  2. Heart involvement in thymic malignancies (10 min)
  3. CNS autoimmunity associated with thymic malignancies – spectrum of clinical and laboratory features and management approach (10 min)
  4. Patients with myasthenia gravis and dilemmas: to use or not neuromuscular blocker; postoperative care for ward or ICU? (10 min)
  5. Q&A (30 min)

09:10 – 09:25 EST – BREAK

09:25 – 10:35 EST  – Session 6: GREAT DEBATE: Adjuvant treatment in TETs (70 min)
  1. Postoperative radiation therapy (PORT) in TNM stage II and stage III TETs  – YES! (10 min)
  2. Postoperative radiation therapy (PORT) in TNM stage II and stage III TETs  – NO! (10 min)
  3. Q&A (15 min)
  4. Adjuvant chemotherapy – YES! (10 min)
  5. Adjuvant chemotherapy – NO! (10 min)
  6. Q&A (15 min)

10:35 – 10:50 EST – BREAK


10:50 – 12:10 EST – Tumor Board (80 min)

12:10 – 12:15 EST – BREAK


12:15 – 12:30 EST – Closing ceremony (15 min) 

In alphabetical order: 

Katarzyna Blasinska, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

Frank Detterbeck, Yale University School of Medicine, New Haven, CT, USA

Vincent Fang, Shanghai Chest Hospital, Shanghai, China 

Conrad Falkson, Queen’s University and Kingston Health Sciences Center, Kingston, Ontario, Canada

Nicolas Girard, Institut Curie, Paris, France

Magdalena Knetki-Wroblewska, Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Ritsuko Komaki, Baylor College of Medicine in Houston TX, USA

Anna Kostera-PruszczykMedical University of Warsaw, Central University Hospital, Warsaw, Poland

Maria Isabel Leite, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK

Edith Marom, The Chaim Sheba Medical Center, Ramat Gan, Israel

Arun RajanNational Cancer Institute, National Institutes of Health (NCI/NIH), Bethesda, USA

Andreas Rimner, Memorial Sloan Kettering Cancer Center, New York, USA

Anja Roden, Mayo Clinic Rochester, Rochester, MN, USA

Paul Van SchilAntwerp University Hospital, Edegem (Antwerp), Belgium

Charles SimoneMemorial Sloan Kettering Cancer Center and New York Proton Center, New York, USA

Malgorzata Szolkowska, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

Jan von der ThüsenDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands

Get to know the preliminary program of ITMIG2022. The topics of the lectures may be slightly changed.

Pathology Workshop

is endorsed by

the European Society of Pathology

ITMIG